# News

## News Releases

### Evidation Insights from 165,000 People Show Continued Growth Potential Amid Uneven Adoption in the GLP-1 Market  
**Date:** July 2, 2026  
**Source:**  
Among 119,000 surveyed individuals actively trying to lose weight, 24% had ever used prescription medication for weight management and 15% had ever used a GLP-1, suggesting significant room for continued market growth as adoption varies by age, gender, and income.

### Evidation Launches Interactive Dermatology Cohort; Shares Preliminary Real-World Insights  
**Date:** March 26, 2026  
**Source:**  
New cohort is designed to address gaps in understanding treatment journeys across the full continuum of care. Insights show that consumer health products play a critical part in how individuals understand and manage their skin conditions.

### Evidation partners with 1upHealth to integrate diverse sources of permissioned real-world health data for research  
**Date:** October 17, 2024  
**Source:**  
Evidation and 1upHealth announce a long-term partnership to advance patient-centered, real-world health research.

### Evidation Launches Temporal Proteomics Platform to Power Autoimmune Research  
**Date:** January 8, 2026  
**Source:**  
New AI-enabled data collection platform will drive the development of novel multimodal datasets for biomarker discovery, treatment-response modeling, and foundation models of the immune system.

### Evidation Shares Insights on Real-World GLP-1 Dosing Behaviors from Over 60,000 Individuals  
**Date:** December 16, 2025  
**Source:**  
New insights from Evidation’s cardiometabolic health and weight management cohort, comprised of over 160,000 individuals, show what factors shape real-world dosing decisions.

### Evidation Appoints Dr. Ghazanfar Khan as Chief Medical Officer  
**Date:** December 2, 2025  
**Source:**  
Evidation appoints Dr. Ghazanfar Khan as Chief Medical Officer. Dr. Khan will advance Evidation’s leadership in real-world data by driving the clinical strategy for direct-to-participant multimodal data collection to fuel AI-powered discovery and evidence generation.

### Evidation Appoints Leslie Oley Wilberforce as CEO  
**Date:** March 6, 2025  
**Source:**  
Evidation appoints Leslie Oley Wilberforce as CEO. Wilberforce will lead Evidation’s next phase of growth in interactive real-world data and health research.

### Trialbee and Evidation partner to accelerate and diversify clinical research recruitment  
**Date:** September 17, 2024  
**Source:**  
Learn how Evidation and Trialbee's joint offering and shared commitment to inclusion and data transparency drives enrollment outcomes.

### Rock Health shares findings from weight care survey with Evidation  
**Date:** July 15, 2024  
**Source:**  
Evidation helped Rock Health conduct surveys that investigated experience and perceptions of a variety of weight care solutions. Read key highlights here.